Plasma Concentrations and Effects of Salbutamol Administered Orally to Patients with Cystic Fibrosis

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1995 Oct 1

PMID 8554933

Authors

R Demnati

M C Michoud

H Ong

P du Souich

Affiliations

Soon will be listed here.

Abstract

1. To test whether cystic fibrosis (CF) altered the kinetics and dynamics of oral salbutamol, 11 patients with CF (19-33 years old; five females; FEV1: 37 +/- 12% of predicted value) and 10 healthy volunteers (20-41 years old; five females; FEV1: 99 +/- 14% of predicted value) received orally 4 mg salbutamol. 2. The estimated pharmacokinetic parameters of salbutamol in patients with CF were identical to those in healthy subjects. For instance, peak plasma concentrations of salbutamol were 10.5 +/- 2.6 (mean +/- s.d.) and 10.2 +/- 2.9 ng ml-1 (NS), and the area under salbutamol plasma concentrations as a function of time (AUC (0, 7 h)) was 43.0 +/- 9.3 ng ml-1 h and 43.3 +/- 12.7 ng ml-1 h (NS) in CF patients and in healthy subjects, respectively. Since on a mg kg-1 dose basis, CF patients received a dose 28% greater than healthy subjects, this lack of differences implies a decrease in the amount of salbutamol absorbed, or alternatively, an increase in both clearance and volume of distribution of salbutamol. 3. Salbutamol did not elicit bronchodilation in CF patients, but increased heart rate from 77 +/- 2 to 103 +/- 3 beats min-1 (P < 0.05). 4. Salbutamol decreased plasma potassium concentrations from 4.5 +/- 0.1 to 3.8 +/- 0.1 mmol l-1 in the CF group (P < 0.05) and from 4.1 +/- 0.2 to 3.4 +/- 0.1 mmol l-1 in the controls (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

References

SVENONIUS E, ARBORELIUS Jr M, Kautto R, Kornfalt R, Lindberg T . Lung function in cystic fibrosis: acute effect of salbutamol. Respiration. 1980; 40(4):226-32. DOI: 10.1159/000194281. View

Guggenbichler J, KIENEL G . Bioavailability of oral antibiotics in cystic fibrosis. Monogr Paediatr. 1979; 10:34-40. View

Kearns G, HILMAN B, Wilson J . Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982; 100(2):312-8. DOI: 10.1016/s0022-3476(82)80663-x. View

KELLY H, Menendez R, Fan L, Murphy S . Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr. 1982; 100(2):318-21. DOI: 10.1016/s0022-3476(82)80664-1. View

Wager J, Fredholm B, LUNELL N, Persson B . Metabolic and circulatory effects of intravenous and oral salbutamol in late pregnancy in diabetic and non-diabetic women. Acta Obstet Gynecol Scand Suppl. 1982; 108:41-6. DOI: 10.3109/00016348209155344. View

Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S . Theophylline disposition in cystic fibrosis. Am Rev Respir Dis. 1983; 127(4):417-21. DOI: 10.1164/arrd.1983.127.4.417. View

Bali A, Stableforth D, Asquith P . Prolonged small-intestinal transit time in cystic fibrosis. Br Med J (Clin Res Ed). 1983; 287(6398):1011-3. PMC: 1549570. DOI: 10.1136/bmj.287.6398.1011. View

Maconochie J, Fowler P . Plasma concentrations of salbutamol after an oral slow-release preparation. Curr Med Res Opin. 1983; 8(9):634-9. DOI: 10.1185/03007998309109811. View

Ziemniak J, Assael B, Padoan R, Schentag J . The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. Eur J Clin Pharmacol. 1984; 26(2):183-9. DOI: 10.1007/BF00630284. View

10.

Ahrens R, Smith G . Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy. 1984; 4(3):105-21. DOI: 10.1002/j.1875-9114.1984.tb03330.x. View

11.

POWELL M, Weisberger M, Gural R, Chung M, Patrick J, Radwanski E . Comparative bioavailability and pharmacokinetics of three formulations of albuterol. J Pharm Sci. 1985; 74(2):217-9. DOI: 10.1002/jps.2600740225. View

12.

Ghignone M, Girling L, Prewitt R . Effects of vasodilators on canine cardiopulmonary function when a decrease in cardiac output complicates an increase in right ventricular afterload. Am Rev Respir Dis. 1985; 131(4):527-30. DOI: 10.1164/arrd.1985.131.4.527. View

13.

Kung M . Parenteral adrenergic bronchodilators and potassium. Chest. 1986; 89(3):322-3. DOI: 10.1378/chest.89.3.322. View

14.

Jonkman J, Freie H, van der Boon W, Grasmeijer G . Single dose absorption profiles and bioavailability of two different salbutamol tablets. Arzneimittelforschung. 1986; 36(7):1133-5. View

15.

Morgan D, Paull J, Richmond B, Wilson-Evered E, Ziccone S . Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol. 1986; 22(5):587-93. PMC: 1401185. DOI: 10.1111/j.1365-2125.1986.tb02939.x. View

16.

Prandota J . Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs. 1988; 35(5):542-78. DOI: 10.2165/00003495-198835050-00004. View

17.

Knoppert D, Spino M, Beck R, Thiessen J, MacLeod S . Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther. 1988; 44(3):254-64. DOI: 10.1038/clpt.1988.147. View

18.

Alvan G, BEERMANN B, Hjelte L, Lind M, Lindholm A, Strandvik B . Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther. 1988; 44(4):436-41. DOI: 10.1038/clpt.1988.177. View

19.

Cheng P, Boat T, Cranfill K, Yankaskas J, Boucher R . Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis. J Clin Invest. 1989; 84(1):68-72. PMC: 303954. DOI: 10.1172/JCI114171. View

20.

Ong H, Adam A, Perreault S, Marleau S, Bellemare M, du Souich P . Analysis of albuterol in human plasma based on immunoaffinity chromatographic clean-up combined with high-performance liquid chromatography with fluorimetric detection. J Chromatogr. 1989; 497:213-21. DOI: 10.1016/0378-4347(89)80020-9. View